<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">CRCM</journal-id><journal-title-group><journal-title>Case Reports in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2325-7075</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/crcm.2021.104013</article-id><article-id pub-id-type="publisher-id">CRCM-108603</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Congenital Dysfibrinogenemia Presented with Massive Hematomas Formed after Hysterectomy
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Kenji</surname><given-names>Niwa</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Kentaro</surname><given-names>Nagata</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Takefumi</surname><given-names>Nakagami</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ryuichiro</surname><given-names>Shimaoka</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Kentaro</surname><given-names>Niwa</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Motoki</surname><given-names>Takenaka</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Takuji</surname><given-names>Tanaka</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Nobuo</surname><given-names>Okumura</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib></contrib-group><aff id="aff5"><addr-line>Department of Diagnostic Pathology &amp;amp; Research Center of Diagnostic Pathology, Gifu Municipal Hospital, Gifu, Japan</addr-line></aff><aff id="aff2"><addr-line>Section of Laboratory Medicine and Obstetrics &amp;amp; Gynecology, Gujo City Hospital, Gujo, Japan</addr-line></aff><aff id="aff3"><addr-line>Department of Obstetrics &amp;amp; Gynecology, Gifu University School of Medicine, Gifu, Japan</addr-line></aff><aff id="aff1"><addr-line>Department of Obstetrics &amp;amp; Gynecology, Gujo City Hospital, Gujo, Japan</addr-line></aff><aff id="aff6"><addr-line>Department of Clinical Laboratory Sciences, School of Health Sciences, Shinshu University, Matsumoto, Japan</addr-line></aff><aff id="aff4"><addr-line>Department of Obstetrics &amp;amp; Gynecology, University of Fukui Hospital, Fukui Prefecture, Japan</addr-line></aff><pub-date pub-type="epub"><day>22</day><month>03</month><year>2021</year></pub-date><volume>10</volume><issue>04</issue><fpage>108</fpage><lpage>116</lpage><history><date date-type="received"><day>19,</day>	<month>March</month>	<year>2021</year></date><date date-type="rev-recd"><day>19,</day>	<month>April</month>	<year>2021</year>	</date><date date-type="accepted"><day>22,</day>	<month>April</month>	<year>2021</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Congenital dysfibrinogenemia (CD) is a qualitative congenital fibrinogen (Fbg) disorder characterized by normal antigen levels of dysfunctional Fbg. A 41-year-old Japanese woman visited the emergent room of our hospital due to acute and severe abdominal pain. Catheterization of the full bladder released her abdominal pain. Magnetic resonance imaging showed a huge pelvic mass, suggesting an intra-mural giant myoma. Before the removal operation of myoma, screening tests showed no abnormalities, including prothrombin time and activated partial thromboplastin time. However, Fbg level was not determined. The patient wanted to receive early surgical treatment, and an abdominal hysterectomy was performed as usual and the intra-operative blood loss was 100 g (ml). However, we found subcutaneous and pelvic hematomas, although active bleeding was not recognized on an emergent computed tomography examination. At that time, we noticed a low level of plasma Fbg (47 mg/dl). We performed a re-laparotomy to remove hematomas. All ligated blood vessels were re-ligated, and oozing points were vaporized. Around the re-operation, six units of fresh frozen plasma and twelve units of red blood cell suspension were transfused. The clinical course after the 2
  <sup>nd</sup> operation was uneventful except for the low level of Fbg. An additional study showed that the value of the Fbg activity and antigen was dissociated, and the patient was diagnosed CD with 
  &amp;gamma;275 Arg to His (CGC to CAC) mutation.
 
</p></abstract><kwd-group><kwd>Dysfibrinogenemia</kwd><kwd> Asymptomatic</kwd><kwd> Major Bleeding Event</kwd><kwd> &amp;gamma;275 Arg to His Mutation</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Congenital fibrinogen disorders comprise two classes of plasma fibrinogen (Fbg) defects: type I, afibrinogenemia or hypofibrinogenemia; and type II, dysfibrinogenemia or hypodysfibrinogenemia, in which there are normal or reduced antigen levels associated with disproportionately low functional activity (qualitative fibrinogen deficiencies) [<xref ref-type="bibr" rid="scirp.108603-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.108603-ref2">2</xref>]. The first patient of congenital dysfibrinogenemia (CD) was recognized in 1955 [<xref ref-type="bibr" rid="scirp.108603-ref3">3</xref>] and the point mutation was reported in Fbg Detroit I in 1968 [<xref ref-type="bibr" rid="scirp.108603-ref4">4</xref>]. Since then, more than 100 mutations and 400 families have been reported [<xref ref-type="bibr" rid="scirp.108603-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.108603-ref2">2</xref>]. About 20% of fibrinogen gene mutations are known to be responsible for thrombosis [<xref ref-type="bibr" rid="scirp.108603-ref5">5</xref>].</p><p>Patients with CD might be identified during the clinical investigation of bleeding [<xref ref-type="bibr" rid="scirp.108603-ref6">6</xref>] or thrombosis [<xref ref-type="bibr" rid="scirp.108603-ref7">7</xref>], or following miscarriage [<xref ref-type="bibr" rid="scirp.108603-ref8">8</xref>]. However, most patients are asymptomatic and are usually discovered by the findings of prolongation of routine parameters of coagulation, such as prothrombin time (PT) and activated partial thromboplastin time (APTT) [<xref ref-type="bibr" rid="scirp.108603-ref9">9</xref>]. The majority of propositi of CD had an incidental diagnosis [<xref ref-type="bibr" rid="scirp.108603-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.108603-ref11">11</xref>]. CD is usually suspected if there is a discrepancy between clottable and immunologic fibrinogen levels.</p><p>We report here an asymptomatic CD case with γ275 Arg to His (CGC to CAC) mutation, presented with massive hematomas formed soon after an abdominal hysterectomy,</p></sec><sec id="s2"><title>2. Case Report</title><p>A 41-year-old Japanese woman, virgin and single, visited the emergent room at Gujo City Hospital due to acute and unbearable abdominal pain. An emergent computed tomography (CT) examination showed full bladder distension due to a giant myoma of the uterus. Catheterization of the bladder released her abdominal pain. Then, she was introduced to the Department of Obstetrics and Gynecology. She had a normal menstrual cycle without hyper- and dysmenorrhea, and had no history of hemorrhagic diathesis and thrombus. magnetic resonance imaging (MRI) showed a huge pelvic mass, suggesting an intra-mural giant myoma in her backside, apart from the endometrium (<xref ref-type="fig" rid="fig1">Figure 1</xref>(A)). Screening tests before the operation showed no abnormalities, including PT and APTT (<xref ref-type="table" rid="table1">Table 1</xref>) and liver functions. She wished to receive an early hysterectomy, and then she underwent an abdominal hysterectomy and bilateral salpingectomy (<xref ref-type="fig" rid="fig1">Figure 1</xref>(B)) for reducing the future ovarian cancer incidence [<xref ref-type="bibr" rid="scirp.108603-ref12">12</xref>], after administering GnRH antagonist for one month. The operation for 121 minutes was performed as usual, and the blood loss was 100 g (ml). The patient showed an uneventful course for approximately six hours after the end of operation, but</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Summary of coagulation test results</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >Parameter (reference values)</th><th align="center" valign="middle"  rowspan="2"  >Pre- operation</th><th align="center" valign="middle"  colspan="3"  >Re-operation</th><th align="center" valign="middle"  colspan="5"  >Day and week after Re-operation</th></tr></thead><tr><td align="center" valign="middle" >Before</td><td align="center" valign="middle" >3 hrs. after</td><td align="center" valign="middle" >8 hrs. after</td><td align="center" valign="middle" >Day 1</td><td align="center" valign="middle" >Day 3</td><td align="center" valign="middle" >Day 5</td><td align="center" valign="middle" >Week 2</td><td align="center" valign="middle" >Week 6</td></tr><tr><td align="center" valign="middle" >PT (80% - 120%)</td><td align="center" valign="middle" >96.9</td><td align="center" valign="middle" >80.9</td><td align="center" valign="middle" >91.7</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >96.9</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >95.1</td><td align="center" valign="middle" >86.4</td></tr><tr><td align="center" valign="middle" >APTT (23 - 38 sec)</td><td align="center" valign="middle" >31.2</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >28.1</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >31.8</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >31.4</td><td align="center" valign="middle" >36.4</td></tr><tr><td align="center" valign="middle" >Active Fibrinogen (180 - 350 mg/dl)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >47</td><td align="center" valign="middle" >76</td><td align="center" valign="middle" >113</td><td align="center" valign="middle" >116</td><td align="center" valign="middle" >122</td><td align="center" valign="middle" >111</td><td align="center" valign="middle" >64</td><td align="center" valign="middle" >61</td></tr><tr><td align="center" valign="middle" >Fibrinogen antigen (180 - 350 mg/dl)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >159</td></tr></tbody></table></table-wrap><p>then she showed abdominal distension with tachycardia and hypotension, suggesting massive bleeding. Emergent CT and laboratory examinations revealed two massive hematomas in the abdominal subcutaneous fat tissue and muscle area (<xref ref-type="fig" rid="fig2">Figure 2</xref>) and the pelvic bottom. The laboratory examination before the re-operation showed a low level of plasma Fbg (47 mg/dl), as listed in <xref ref-type="table" rid="table1">Table 1</xref>. After then, we decided to perform a re-laparotomy after preparation of fresh frozen plasma (FFP) and red blood cell (RBC) suspension. At the re-laparotomy, one bigger hematoma under the abdominal muscle fascia and the other smaller on the pelvic floor after hysterectomy was present, but apparent bleeding points could not be detected. Hematomas were removed, and all ligated blood vessels were re-ligated. Some oozing points were vaporized by the electrocision. The blood loss including hematomas was 801 g (ml). Six units of FFP and twelve units of RBC suspension were transfused before and after the re-operation. After the 2<sup>nd</sup> operation, the clinical course was uneventfully excepted with low level of Fbg activity (<xref ref-type="table" rid="table1">Table 1</xref>). The post-operative course of the 2<sup>nd</sup> operation was uneventful and the patient was discharged on 6<sup>th</sup> day after the 2<sup>nd</sup> operation. Pathological examination of a giant uterine tumor revealed leiomyoma (<xref ref-type="fig" rid="fig3">Figure 3</xref>), and two weeks after the operation, the Fbg activity showed still the low level (<xref ref-type="table" rid="table1">Table 1</xref>). After then, we decided to determine the differential diagnosis of low or dysfibrinogenemia; therefore consulted Prof. Okumura, Shinshu University, who is an expert of CD and one of the co-authors. As the value of the Fbg activity and antigen was dissociated (<xref ref-type="table" rid="table1">Table 1</xref>), dysfibrinogenemia rather than hypofibrinogenemia was considered [<xref ref-type="bibr" rid="scirp.108603-ref13">13</xref>]. Thus, we analyzed the mutation(s) of fibrinogen genes, FGA, FGB and FGG [<xref ref-type="bibr" rid="scirp.108603-ref14">14</xref>]. Genetic analysis was approved by the Ethical Review Board of Shinshu University School of Medicine (#603) and after informed consent had been obtained from the patient, blood samples were collected. Polymerase chain reaction-amplification of the Fbg gene was performed and direct DNA sequencing was done as described in a previous report [<xref ref-type="bibr" rid="scirp.108603-ref12">12</xref>]. A G to A substitution resulted in the replacement of wild-type Arg at residue 275 by His (<xref ref-type="fig" rid="fig4">Figure 4</xref>) [<xref ref-type="bibr" rid="scirp.108603-ref14">14</xref>]. The patient was diagnosed CD with γ275 Arg to His (CGC to CAC).</p><p>After nine months of the 2<sup>nd</sup> surgery, the patient is healthily without hemorrhage and thrombosis episodes. After diagnosing the patient, we interviewed her family medical history, including hemorrhage or thrombosis episodes, and commissioned to examine the level of Fbg activity of her family in another hospital. Her father and brother were confirmed to be the low level of Fbg activity, but they had no episodes of hemorrhage or thrombosis. The mutations of fibrinogen gene of this patient’s father and brother have not been examined.</p></sec><sec id="s3"><title>3. Discussion</title><p>The present patient remained asymptomatic until the hematomas formed after the 1<sup>st</sup> operation. An accidental injury of the venule might occur because of a little blood loss [100 g (ml)] of the 1<sup>st</sup> operation. After forming subcutaneous hematoma, the Fbg might be consumed and the second hematoma might form in the abdominal cavity/pelvic bottom. Most gynecological manifestations of CD cases [<xref ref-type="bibr" rid="scirp.108603-ref10">10</xref>], even presently are thought to be menorrhagia, spontaneous recurrent abortion, antepartum and postpartum hemorrhage [<xref ref-type="bibr" rid="scirp.108603-ref13">13</xref>]. However, this patient had no bleeding episode, including menorrhagia, spontaneous recurrent abortion, and antepartum/postpartum hemorrhage, as she did not experience pregnancy.</p><p>Determining intraperitoneal hemorrhage and its causes by diagnostic imaging including abdominal ultrasonography, CT and MRI are thought to be critical to treatment planning. Especially, enhanced CT might be the best tool for determining active bleeding [<xref ref-type="bibr" rid="scirp.108603-ref15">15</xref>]. In the present case, two large hematomas, but no active bleeding, were observed on an emergent CT.</p><p>In general, Fbg is an abundant protein synthesized in the liver, present in human blood plasma at concentrations ranging 180 - 350 mg/dl in healthy individuals with a normal half-life of 3 - 5 days [<xref ref-type="bibr" rid="scirp.108603-ref16">16</xref>]. Before the 2<sup>nd</sup> operation, we found that the Fbg (activity) was low level [47 (mg/dl)]. The patient showed the low level of Fbg up to 6 months after the operation. After the preparation of FFP, we removed the hematomas and do stanching operations. The differential diagnosis of low and dysfibrinogenemia should be done. In this case, as the value of the Fbg activity and antigen was dissociated, we considered dysfibrinogenemia rather than hypofibrinogenemia [<xref ref-type="bibr" rid="scirp.108603-ref13">13</xref>].</p><p>For the definitive diagnosis, a G to A substitution resulted in the replacement of wild-type Arg at residue 275 by His [<xref ref-type="bibr" rid="scirp.108603-ref14">14</xref>]. The patient was diagnosed CD with γ275 Arg to His (CGC to CAC). CD is generally associated with autosomal dominant inheritance caused by heterozygosity for missense mutations [<xref ref-type="bibr" rid="scirp.108603-ref13">13</xref>]. The most frequent mutations are substitutions in the N-terminal region of Aα chain or in the C-terminal region of the γ chain that result in defective interaction between the two terminal D regions and the E region, or in defective D:D interactions, thus causing a defect in the assembly of fibrin in early clot formation [<xref ref-type="bibr" rid="scirp.108603-ref17">17</xref>]. Mutations in exon 2 of FGA and exon 8 of FGG account for almost 85% of all CD mutations [<xref ref-type="bibr" rid="scirp.108603-ref13">13</xref>]. The present case showed γ275 Arg to His mutation in exon 8 of FGG. Several reports described same mutation in the CD patients [<xref ref-type="bibr" rid="scirp.108603-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.108603-ref18">18</xref>] [<xref ref-type="bibr" rid="scirp.108603-ref19">19</xref>] [<xref ref-type="bibr" rid="scirp.108603-ref20">20</xref>]. The R275 residue is known to be the most commonly mutated site in the globular carboxyl-terminal region of the γ-chain [<xref ref-type="bibr" rid="scirp.108603-ref21">21</xref>]. Usually, affected individuals do not show thrombo-embolic complications. However, thrombotic complications were reported in three of the nine families with heterozygous mutations encoding Arg275 → His substitutions [<xref ref-type="bibr" rid="scirp.108603-ref18">18</xref>]. While no bleeding or thrombotic events have occurred in the patient’s family, it is possible that thrombotic or hemorrhagic events may occur in the future, especially in the case of surgery, delivery, or trauma [<xref ref-type="bibr" rid="scirp.108603-ref22">22</xref>]. Therefore, the patient and her family still need follow-up to prevent thrombosis, bleeding, or other related events.</p><p>As for CDs, bleeding is generally mild, and also PT and APTT tests in most cases showed normal range, as shown in this case [<xref ref-type="bibr" rid="scirp.108603-ref9">9</xref>]. As the pre-operative screening test for suspicious for massive hemorrhage during operation, Fbg must be included especially in CD’s relatives living areas. When suspected for CD who will receive operation for cardiovascular and/or major bleeding, FFP or cryoprecipitate should be prepared before the operation [<xref ref-type="bibr" rid="scirp.108603-ref13">13</xref>].</p></sec><sec id="s4"><title>4. Conclusion</title><p>CD is a qualitative Fbg disorder characterized by normal antigen levels of a dysfunctional Fbg. We presented a 41-year-old Japanese woman who received an abdominal hysterectomy as usual, but hematomas formed after the operation. The dissociated values of Fbg activity and antigen suggested dysfibrinogenemia and genetic analysis revealed CD with γ275 Arg to His (CGC to CAC) mutation.</p></sec><sec id="s5"><title>Consent</title><p>Verbal consent was obtained from the patient before writing this case report.</p></sec><sec id="s6"><title>Ethical Approval</title><p>This was obtained from the ethical committee of our hospital before writing this case report.</p></sec><sec id="s7"><title>Acknowledgements</title><p>We thank the editor and reviewers for the constructive comments, which helped us to improve the manuscript. This case report was approved by the patient verbal consent.</p></sec><sec id="s8"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s9"><title>Cite this paper</title><p>Niwa, K., Nagata, K., Nakagami, T., Shimaoka, R., Niwa, K., Takenaka, M., Tanaka, T. and Okumura, N. (2021) Congenital Dysfibrinogenemia Presented with Massive Hematomas Formed after Hysterectomy. Case Reports in Clinical Medicine, 10, 108-116. https://doi.org/10.4236/crcm.2021.104013</p></sec></body><back><ref-list><title>References</title><ref id="scirp.108603-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">de Moerloose, P., Casini, A. and Neerman-Arbez, M. (2013) Congenital Fibrinogen Disorders: An Update. Seminars in Thrombosis and Hemostasis, 39, 585-595. https://doi.org/10.1055/s-0033-1349222</mixed-citation></ref><ref id="scirp.108603-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Neerman-Arbez, M. and Casini, A. (2018) Clinical Consequences and Molecular Bases of Low Fibrinogen Levels. International Journal of Molecular Sciences, 19, 192. https://doi.org/10.3390/ijms19010192</mixed-citation></ref><ref id="scirp.108603-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Ingram, G.I. (1955) Variations in the Reaction between Thrombin and Fibrinogen and Their Effect on the Prothrombin Time. Journal of Clinical Pathology, 8, 318-323. https://doi.org/10.1136/jcp.8.4.318</mixed-citation></ref><ref id="scirp.108603-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Blomback, M., Blomback, B., Mammen, E.F. and Prasad, A.S. (1968) Fibrinogen Detroit—A Molecular Defect in the N-Terminal Disulphide Knot of Human Fibrinogen? Nature, 218, 134-137. https://doi.org/10.1038/218134a0</mixed-citation></ref><ref id="scirp.108603-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Yoshida, S., Kibe, T., Matsubara, R., Koizumi, S.I., Nara, K., Amano, K. and Okumura, N. (2017) Congenital Dysfibrinogenemia in a Japanese Family with Fibrinogen Naples (BβAla68Thr) Manifesting as Superior Sagittal Sinus Thrombosis. Blood Coagulation and Fibrinolysis, 28, 580-584. https://doi.org/10.1097/MBC.0000000000000641</mixed-citation></ref><ref id="scirp.108603-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Brennan, S.O., Mosesson, M.W., Lowen, R. and Frantz, C. (2006) Dysfibrinogenemia (Fibrinogen Wilmington) Due to a Novel Αα Chain Truncation Causing Decreased Plasma Expression and Impaired Fibrin Polymerization. Thrombosis and Haemostasis, 96, 88-89. https://doi.org/10.1160/TH05-11-0749</mixed-citation></ref><ref id="scirp.108603-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">de Raucourt, E., Fischer, A.M., Meyer, G. and de Mazancourt, P. (2006) A Bβ 14 Arg→Cys Fibrinogen Variant in a Patient with Thrombotic Complications (Fibrinogen St-Germain III). Journal of Thrombosis and Haemostasis, 4, 2722-2723. https://doi.org/10.1111/j.1538-7836.2006.02240.x</mixed-citation></ref><ref id="scirp.108603-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Dempfle, C.E., George, P.M., Borggrefe, M., Neumaier, M. and Brennan, S.O. (2009) Demonstration of Heterodimeric Fibrinogen Molecules Partially Conjugated with Albumin in a Novel Dysfibrinogen: Fibrinogen Mannheim V. Thrombosis and Haemostasis, 102, 29-34. https://doi.org/10.1160/TH08-09-0559</mixed-citation></ref><ref id="scirp.108603-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Cunningham, M.T., Brandt, J.T., Laposata, M. and Olson, J.D. (2002) Laboratory Diagnosis of Dysfibrinogenemia. Archives of Pathology &amp; Laboratory Medicine, 126, 499-505. https://doi.org/10.5858/2002-126-0499-LDOD</mixed-citation></ref><ref id="scirp.108603-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Casini, A., Blondon, M., Lebreton, A., Koegel, J., Tintillier, V., de Maistre, E., Gautier, P., Biron, C., Neerman-Arbez, M. and de Moerloose, P. (2015) Natural History of Patients with Congenital Dysfibrinogenemia. Blood, 125, 553-561. https://doi.org/10.1182/blood-2014-06-582866</mixed-citation></ref><ref id="scirp.108603-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Casini, A., Neerman-Arbez, M., Ariens, R.A. and de Moerloose, P. (2015) Dysfibrinogenemia: From Molecular Anomalies to Clinical Manifestations and Management. Journal of Thrombosis and Haemostasis, 13, 909-919. https://doi.org/10.1111/jth.12916</mixed-citation></ref><ref id="scirp.108603-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Anggraeni, T.D., Al Fattah, A.N. and Surya, R. (2018) Prophylactic Salpingectomy and Ovarian Cancer: An Evidence-Based Analysis. South Asian Journal of Cancer, 7, 42-45. https://doi.org/10.4103/sajc.sajc_187_17</mixed-citation></ref><ref id="scirp.108603-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Yoda, M., Kaido, T., Taira, C., Higuchi, Y., Arai, S. and Okumura, N. (2020) Congenital Fibrinogen Disorder with a Compound Heterozygote Possessing Two Novel FGB Mutations, One Qualitative and the Other Quantitative. Thrombosis Research, 196, 152-158. https://doi.org/10.1016/j.thromres.2020.08.031</mixed-citation></ref><ref id="scirp.108603-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Terasawa, F., Okumura, N., Higuchi, Y., Ishikawa, S., Tozuka, M., Ishida, F., Kitano, K. and Katsuyama, T. (1999) Fibrinogen Matsumoto III: A Variant with Γ275 Arg→Cys (CGC→TGC)—Comparison of Fibrin Polymerization Properties with Those of Matsumoto I (Γ364 Asp→His) and Matsumoto II (Γ308 Asn→Lys). Thrombosis and Haemostasis, 81, 763-766. https://doi.org/10.1055/s-0037-1614568</mixed-citation></ref><ref id="scirp.108603-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Willmann, J.K., Roos, J.E., Platz, A., Pfammatter, T., Hilfiker, P.R., Marincek, B. and Weishaupt, D. (2002) Multidetector CT: Detection of Active Hemorrhage in Patients with Blunt Abdominal Trauma. AJR American Journal of Roentgenology, 179, 437-444. https://doi.org/10.2214/ajr.179.2.1790437</mixed-citation></ref><ref id="scirp.108603-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Vilar, R., Fish, R.J., Casini, A. and Neerman-Arbez, M. (2020) Fibrin (Ogen) in Human Disease: Both Friend and Foe. Haematologica, 105, 284-296. https://doi.org/10.3324/haematol.2019.236901</mixed-citation></ref><ref id="scirp.108603-ref17"><label>17</label><mixed-citation publication-type="book" xlink:type="simple">N.-A., M. and de Moerloose, P. (2010) Hereditary Fibrinogen Abnormalities. In: Kaushansky, K., Lichtman, M., Beutler, E., Kipps, T., Prchanl, J. and Seigsohn, U., Eds., Williams Hematology, McGraw-Hill, New York, 1-33.</mixed-citation></ref><ref id="scirp.108603-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Linenberger, M.L., Kindelan, J., Bennett, R.L., Reiner, A.P. and Cote, H.C. (2000) Fibrinogen Bellingham: A Γ-Chain R275C Substitution and a Β-Promoter Polymorphism in a Thrombotic Member of an Asymptomatic Family. American Journal of Hematology, 64, 242-250. https://doi.org/10.1002/1096-8652(200008)64:4&lt;242::AID-AJH2&gt;3.0.CO;2-O</mixed-citation></ref><ref id="scirp.108603-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Yamazumi, K., Terukina, S., Onohara, S. and Matsuda, M. (1988) Normal Plasmic Cleavage of the Γ-Chain Variant of “Fibrinogen Saga” with an Arg-275 to His Substitution. Thrombosis and Haemostasis, 60, 476-480. https://doi.org/10.1055/s-0038-1646994</mixed-citation></ref><ref id="scirp.108603-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Terukina, S., Matsuda, M., Hirata, H., Takeda, Y., Miyata, T., Takao, T. and Shimonishi, Y. (1988) Substitution of ΓArg-275 by Cys in an Abnormal Fibrinogen, “Fibrinogen Osaka II”. Evidence for a Unique Solitary Cystine Structure at the Mutation Site. Journal of Biological Chemistry, 263, 13579-13587. https://doi.org/10.1016/S0021-9258(18)68281-X</mixed-citation></ref><ref id="scirp.108603-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Cote, H.C., Lord, S.T. and Pratt, K.P. (1998) Γ-Chain Dysfibrinogenemias: Molecular Structure-Function Relationships of Naturally Occurring Mutations in the Γ Chain of Human Fibrinogen. Blood, 92, 2195-2212.</mixed-citation></ref><ref id="scirp.108603-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Alving, B.M. and Henschen, A.H. (1987) Fibrinogen Giessen I: A Congenital Homozygously Expressed Dysfibrinogenemia with Aα 16 Arg ← His Substitution. American Journal of Hematology, 25, 479-482. https://doi.org/10.1002/ajh.2830250414</mixed-citation></ref></ref-list></back></article>